Professionals
Practice Areas
- Anti-Counterfeiting
- Chemical and Material Sciences Practice
- Consumer Products Practice
- Due Diligence in IP Acquisitions
- Foreign & PCT Patent Filing
- IP Transactional
- Licensing
- Life Sciences Practice
- Patent Landscaping and Risk Analysis
- Patents
- Pharmaceutical Patent Services
- Pharmaceutical Practice
- Product Clearance
- Technology Transfer
- Utility, Design, and Plant Patent Filing with the USPTO
Technologies
- Biotechnology
- Chemistry
- Food Science
- Medical Devices
- Pharmaceuticals & Pharmaceutical Formulation
- Polymer & Materials Science
Honors
- Nominated by Southern Illinois University School of Medicine and accepted into the AAAS/Science Program for Excellence in Science
- Goodarzi and White Memorial Foundation award from Southern Illinois University School of Medicine
- First place for China National Biology Olympiad (CNBO)
Admissions
- U.S. Patent and Trademark Office, 2011
Education
- Southern Illinois University, Doctor of Philosophy (Ph.D.), Biochemistry, Microbiology and Molecular Biology, 2005 - 2010
- Shandong University, Biotechnology and Life Science, Bachelor of Science (BS), 2002 - 2005
Languages
- English: Full professional proficiency
- Chinese (Mandarin): Native or bilingual proficiency
Dr. Yong Tang’s practice focuses on biotechnology and life science, particularly in the pharmaceutical products (e.g., small molecules, oncolytic virus therapy, biologics, monoclonal antibodies, and antibody-drug conjugates) and medical devices (e.g., navigational bronchoscopy, intratumoral drug injection, microneedles, autoinjector, wearable drug delivery device, robotic-assisted surgery, drug-coated implants and sustained drug release). He also has over 12 years of IP and technology consulting experience spanning across the areas of consumer goods, food and beverage ingredients, biopolymers, antibody discovery, robotic surgery and telehealth.
Prior to joining Cantor Colburn, Dr. Tang managed a range of IP consulting projects, including patentability and prior art search, IP landscaping, patent portfolio analysis, competitive intelligence, due diligence investigations, partnership identification, technology scouting, evaluation, and licensing. He has extensive experience in IP searches, utilizing a variety of methods including keywords, patent classifications, gene sequences, citations, and corporate tree. He directed technical intelligence projects for corporations, research institutions, and economic development entities. Dr. Tang, an IBM-certified data scientist, leveraged his expertise in IP data mining and big data analytics to uncover technology trends and identify key commercialization and licensing opportunities. His work focused on translating complex datasets into actionable insights, enabling strategic decisions in intellectual property and technology management.
In addition to his IP practice, Dr. Tang was a prolific research scientist and spent seven years in cancer research on drug combination-mediated synergistic cancer treatment, drug-metabolizing enzyme and transporter-mediated multidrug resistance, and G protein-coupled receptor (GPCR) involved apoptosis and autophagy in colon cancer. Yong is the author or co-author of more than twenty peer-reviewed research articles and gave more than fifteen presentations in national or international conferences. The NIH-National Cancer Institute (NCI) funded Dr. Tang, with the Ruth L. Kirschstein National Research Service Award (NRSA) and Institutional Research Training Grants. Fluent in both English and Mandarin, Dr. Tang brings a unique interdisciplinary approach to his practice.
Experience Highlights
- Patent Agent, Cantor Colburn LLP, 2024 - present
- Senior Patent Agent and VP of IP Data Science, Perception Partners, 2020 - 2024
- Patent Agent and Director of IP Analytics, Perception Partners, 2015 - 2020
- Patent Agent and IP Analytics Manager, Perception Partners, 2012 - 2015
- Postdoctoral Fellow, Virginia Commonwealth University, 2010 - 2012
- Graduate Research Assistant, Southern Illinois University, 2005 - 2010
- Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria mediated apoptotic cell death (Cell Death & Differentiation; April 2011; 200+ citations)
- G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer (International Journal of Cancer; February 2011; 300+ citations)
- Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters (Biochemical Pharmacology; April 2012; 250+ citations)
- Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells (Cancer Biology & Therapy; May 2012)
- Lapatinib and Obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress (Molecular Pharmacology; December 2012)
- Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors (Molecular Pharmacology; August 2012)
- Obatoclax and Lapatinib interact to induce toxic autophagy through NOXA (Molecular Pharmacology; April 2012)
- Enhancing CHK1 inhibitor lethality in glioblastoma (Cancer Biology & Therapy; April 2012)
- Current advances in ER stress intervention therapies (Endoplasmic Reticulum Stress in Health and Disease Chapter; book chapter; January 2012)
- Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells (Autophagy; October 2011)
- Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death (Cancer Biology & Therapy; August 2011)
- CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle (Molecular Interventions; April 2011)
- The role of short-chain fatty acids in orchestrating two types of programmed cell death in colon cancer (Autophagy; February 2011)
- Camptothecin attenuates Cytochrome P450 3A4 induction by the antagonism of human Pregnane X Receptor (Journal of Pharmacology and Experimental Therapeutics; September 2010)
- Regulation of drug resistance by human pregnane X receptor (PXR) in breast cancer (Cancer Biology & Therapy; July 2009)
- Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer (International Journal of Cancer; April 2009)
- Role of Rho GTPases in breast cancer (Frontiers in Bioscience; January 2008; 140+ citations)
- Human pregnane X receptor and resistance to chemotherapy in prostate cancer (Cancer Research; November 2007; 170+ citations)
News
- September 30, 2024
Cantor Colburn welcomes Ph.D. Organic Chemists and Patent Agents Naresh Ramireddy and Yong Tang to the firm's Atlanta office.
Professional Affiliations
- The Chinese Antibody Society
- American Association for the Advancement of Science (AAAS)
- Strategic Consortium of Intelligence Professionals (SCIP)
- Intellectual Property Owners Association (IPO)
